| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Advancing SION-451 + SION-2222 dual combination to AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in the first quarter of 2027 |
| 14 Sep 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +1 more
Post hoc analyses of SION-719 PreciSION CF subset showed a mean placebo-adjusted sweat chloride |
| 10 Aug 2026 |
8-K: Other Events
SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard of care |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care is on track for topline data summer of 2026 |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, Sionna Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders, at which a quorum was present. There were 45,142,330 shares of the Company's common stock outstanding as of the record date of April 21,... |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026 |
| 02 Mar 2026 |
8-K: Results of Operations and Financial Condition
Ongoing PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis is on track with topline data anticipated in mid-2026 |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Initiated PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis |
| 11 Aug 2025 |
8-K: Results of Operations and Financial Condition
Announced Positive Phase 1 data for SION-719 and SION-451 demonstrating both first-in-class NBD1 stabilizers were generally well tolerated and exceeded pharmacokinetic targets |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 12, 2025, Sionna Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders, at which a quorum was present. There were 44,124,394 shares of the Company's common stock outstanding as of the record date of April 15,... |
| 04 Jun 2025 |
8-K: Regulation FD Disclosure
SION-719 and SION-451 were generally well tolerated and achieved desired pharmacokinetic targets that |
| 12 May 2025 |
8-K: Results of Operations and Financial Condition
Phase 1 dosing completed for NBD1 stabilizers SION-719 & SION-451; both compounds continue to be generally well tolerated |
| 20 Mar 2025 |
8-K: Results of Operations and Financial Condition
Phase 1 MAD dosing completed for SION-451 and final MAD cohort of SION-719 planned; Interim data in healthy volunteers show potential to provide clinically meaningful benefit to CF patients. Topline data anticipated in first half of 2025 |
| 10 Feb 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States that is fixed by or i... |
Loading...